Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

The Garden State is looking to grow into the next big biotech hub. | The Garden State is looking to grow into the next big ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA ...

In its yearly survey of international clinicians and patients, Philips illustrated significant gaps in people’s trust when it ...

Julius Clinical is intertwining its roots with that of Peachtree BioResearch Solutions. | Netherlands-based Julius Clinical ...

When it comes to training artificial intelligence, OpenAI and Babylon Biosciences have shown that experienced hands can help ...

The medtech association AdvaMed went to Capitol Hill today to make the case that the medical device industry should be exempt ...

Industry layoffs continue to accelerate, this time hitting RA Capital’s biotech incubator, according to Stat News ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...